Table 3.
Baseline characteristics of women enrolled in the four studies presented in the meta-analysis.
| Study [reference] | Age mean (SD) | HPV 16 positivity at enrolment (%) | HPV 18 positivity at enrolment (%) | Lifetime number of sexual partners (median) | Smoking status (%) | Chlamydia trachomatis (%) | Hormonal contraceptive use (%) | Cytological abnormality at entry (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA | Serology | DNA | Serology | ||||||||||||||||||
| V | C | V | C | V | C | V | C | V | C | V | C | V | C | V | C | V | C | V | C | ||
| GSK [11, 12, 28] | 20 ± 3 | 21 ± 3 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
| PATRICIA [13, 27] | 20 ± 3 | 20 ± 3 | 14 | 14 | 2 | 1 | 11 | 10 | 1 | 1 | 0 ∗ | 4% | 4% | 30 | 30 | 6 | 5 | 59 | 61 | 10 | 9 |
| 1 ∗ | 74% | 74% | |||||||||||||||||||
| 2 ∗ | 14% | 15% | |||||||||||||||||||
| ≥3 ∗ | 8% | 8% | |||||||||||||||||||
| FUTURE I [16, 26, 30] | 20 ± 2 | 20 ± 2 | 9 | 8 | 12 | 12 | 3 | 3 | 3 | 3 | 2 | 2 | 26 | 26 | 4 | 5 | 58 | 57 | 11 | 12 | |
| FUTURE II [17, 26, 30] | 20 ± 2 | 20 ± 2 | 9 | 9 | 11 | 11 | 4 | 4 | 4 | 4 | 2 | 2 | NR | NR | 4 | 4 | 59 | 60 | 12 | 11 | |
V: vaccine group; C: control group; NR: not reported.
∗Results are presented as percentage of women stratified by number of sexual partners.